10-Q/A: Accuray Restates Q1 2026 Financials, Cites RPO Errors

Accuray Incorporated filed an amended quarterly report to restate its September 30, 2025 financial information due to errors in remaining performance obligations and identified material weaknesses in internal controls.

Summary

• Accuray Incorporated filed an amended Quarterly Report on Form 10-Q/A for the period ended September 30, 2025, to restate its previously issued interim financial information.
• The restatement was primarily due to errors related to the methodology applied for determining whether executed open system orders, upgrade sales orders, and customer credits represent Remaining Performance Obligations (RPO) in accordance with ASC 606.
• The company incorrectly included certain balances within the RPO footnote, as customer deposits at order inception did not represent substantive termination penalties.
• The total remaining performance obligations were reduced from $866.0 million (previously reported) to $59.3 million as of September 30, 2025.
• This reduction reflects the exclusion of $760.7 million of open system sales orders, $22.3 million of open upgrade orders, and $23.8 million in customer credits.
• The errors did not impact the unaudited Condensed Consolidated Balance Sheets, Statements of Operations and Comprehensive Loss, Statements of Stockholders Equity, or Statements of Cash Flows for the period ended September 30, 2025.
• The Audit Committee concluded that the previously issued financial information for the three months ended September 30, 2025, should no longer be relied upon.
• Management reevaluated its disclosure controls and procedures (DCP) and internal control over financial reporting (ICFR), concluding they were not effective as of September 30, 2025.
• Two material weaknesses were identified: 1) the review of footnote schedules supporting financial statement disclosures, and 2) inadequate controls to appropriately analyze all relevant information for complete and accurate GAAP presentation and disclosure, principally from incorrect assessment during the initial adoption of ASC 606.
• Net loss for the three months ended September 30, 2025, was $(21,678) thousand, compared to $(3,954) thousand for the same period in 2024.
• Total net revenue for the three months ended September 30, 2025, was $93,942 thousand, a decrease from $101,545 thousand in 2024.
• Gross profit decreased to $26,548 thousand in Q1 2026 from $34,469 thousand in Q1 2025.
• Operating expenses increased to $37,861 thousand in Q1 2026 from $36,618 thousand in Q1 2025.
• Cash and cash equivalents increased to $63,344 thousand as of September 30, 2025, from $57,416 thousand as of June 30, 2025.
• Total liabilities increased to $394,949 thousand as of September 30, 2025, from $389,070 thousand as of June 30, 2025.
• Total stockholders' equity decreased to $61,867 thousand as of September 30, 2025, from $81,169 thousand as of June 30, 2025.
• The company initiated a cost savings initiative in Q1 2026, reducing its global workforce by approximately 3%, resulting in a restructuring charge of $1.5 million for severance benefits and $1.3 million for consulting activities.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative filing due to the significant restatement of a key financial metric (RPO), the admission of material weaknesses in internal controls, and deteriorating financial performance with increased losses and decreased revenue.

Positives

• Cash and cash equivalents increased to $63,344 thousand as of September 30, 2025, from $57,416 thousand as of June 30, 2025.
• Net cash provided by operating activities was $12,180 thousand for the three months ended September 30, 2025, compared to net cash used of $(7,294) thousand in the prior year period.
• The company was in compliance with its covenants and other requirements of the Financing Agreement as of September 30, 2025.
• Income from equity method investment (joint venture) was $439 thousand for the three months ended September 30, 2025, compared to a loss of $(72) thousand in the prior year period.

Negatives

• The company restated its previously issued interim financial information for the three months ended September 30, 2025, due to errors in Remaining Performance Obligations (RPO).
• The RPO balance was significantly reduced from $866.0 million (previously reported) to $59.3 million, indicating a substantial overstatement of future revenue commitments.
• Management concluded that disclosure controls and procedures were not effective and identified material weaknesses in internal control over financial reporting as of September 30, 2025.
• Net loss significantly widened to $(21,678) thousand for the three months ended September 30, 2025, compared to $(3,954) thousand in the prior year period.
• Total net revenue decreased to $93,942 thousand for the three months ended September 30, 2025, from $101,545 thousand in the prior year period.
• Gross profit decreased to $26,548 thousand in Q1 2026 from $34,469 thousand in Q1 2025.
• Operating expenses increased to $37,861 thousand in Q1 2026 from $36,618 thousand in Q1 2025.
• Interest expense significantly increased to $(8,052) thousand in Q1 2026 from $(2,955) thousand in Q1 2025.
• The company recorded a loss from change in fair value of warrant liability of $(1,874) thousand in Q1 2026.
• Total stockholders' equity decreased to $61,867 thousand as of September 30, 2025, from $81,169 thousand as of June 30, 2025.
• The company implemented a cost savings initiative involving a 3% global workforce reduction, incurring $1.5 million in severance and $1.3 million in consulting costs.
• Sales of products to the joint venture decreased significantly to $8,847 thousand for the three months ended September 30, 2025, from $28,644 thousand in the prior year period.

Risks

• The company faces risks related to the current global economic environment, including inflation, high interest rates, foreign currency exchange rate fluctuations, and geopolitical concerns (Russia-Ukraine, Middle East, China-U.S. tensions), which could adversely affect business.
• Ongoing supply chain and inflation challenges are significant headwinds expected to affect gross margins and net income (loss) through at least fiscal year 2026.
• Reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines in the U.S., have negatively impacted net revenue since fiscal year 2024 and are expected to continue through fiscal year 2026.
• Failure to comply with covenants in the Financing Agreement could adversely affect the company's ability to finance future operations or capital needs, with substantially all assets pledged as collateral.
• Inability to achieve widespread market acceptance for CyberKnife or TomoTherapy platforms could prevent necessary revenue generation.
• Difficulty in maintaining or increasing gross margins on product sales and services, impacted by manufacturing yields, production volume, selling prices, increased labor/material costs, supply chain disruptions, and increased service/warranty costs.
• Substantial indebtedness ($152.4 million outstanding borrowings, $18.0 million convertible senior notes) and potential future debt may adversely affect financial condition.
• Past non-compliance with financial covenants required waivers, and there is no certainty of future waivers if needed.
• Enhanced international tariffs (U.S. and China) could decrease product sales volume in China and increase costs.
• Operating results, cash flows, quarterly orders, revenues, and margins are unpredictable and fluctuate significantly.
• Intense competition and rapid technological change in the medical device industry could render products obsolete.
• Risks from international operations, including economic/political instability, import delays, changes in foreign laws, protectionist policies, and foreign currency fluctuations.
• Manufacturing problems or failure to meet federal, state, or foreign manufacturing standards could lead to temporary cessation of operations, delays, and lost revenue.
• Inability to develop new products or enhance existing ones to meet customer needs and compete favorably.
• Potential product liability claims, recalls, other field actions, and warranty claims that could be expensive and divert management attention.
• Reliance on single-source suppliers for critical components, increasing vulnerability to supply chain disruptions and cost increases.
• Dependence on key employees and the ability to attract and retain talent.
• Disruption of critical information technology systems, infrastructure, data, or cyberattacks could harm business.
• Failure to comply with privacy, cybersecurity, and data protection laws (HIPAA, GDPR, PIPL, CCPA, CPRA) could result in penalties.
• Insufficient coverage and reimbursement from third-party payors for product use could adversely affect demand.
• Safety and efficacy of products for certain uses are not yet supported by long-term clinical data.
• Failures or disruptions at logistics providers could adversely impact business.
• Third parties may claim intellectual property infringement or violation of license agreements.
• Difficulty and cost in protecting intellectual property.
• Unfavorable results of legal proceedings could materially and adversely affect financial condition.
• Long and variable sales and installation cycles for products contribute to volatile revenues and cash flows.
• Dependence on third-party distributors in international markets.
• Risks associated with collaborations, partnerships, strategic alliances, and joint ventures, including the JV in China with a state-owned entity.
• Inability to successfully complete or integrate acquisitions.
• Inability to raise capital or obtain financing in the future.
• Inability to fully utilize certain tax loss carryforwards due to Section 382 limitations.
• Changes in interpretation or application of generally accepted accounting principles may adversely affect operating results.
• Operations are vulnerable to interruption or loss because of climate change, natural disasters, global or regional health pandemics or epidemics, terrorist acts and other events beyond control.

Future Outlook

The company expects gross margins and net income (loss) to continue to be adversely affected by increased material costs and freight and logistics expenses through at least fiscal year 2026. Inflation and ongoing supply chain challenges are also expected to impact cash from operations through at least fiscal year 2026. Reduced budgets and lower capital deployment priority for radiotherapy equipment in the U.S. are expected to continue impacting net revenue through fiscal year 2026. The cost-saving initiative involving workforce reduction is expected to be substantially completed by the fourth quarter of fiscal year 2026.

Management Comments

• Stephen La Neve (CEO) certified that the report does not contain any untrue statement of a material fact or omit to state a material fact, and that financial statements fairly present financial condition, results of operations, and cash flows.
• Stephen La Neve (CEO) also certified responsibility for establishing and maintaining disclosure controls and internal control over financial reporting, their design, evaluation, and disclosure of changes or weaknesses.
• Ali Pervaiz (SVP & CFO) provided similar certifications regarding the accuracy of the report and the effectiveness of disclosure controls and internal control over financial reporting.

Industry Context

StockSavvy.ai notes that the medical device industry, particularly in oncology, faces intense competition and rapid technological change. Macroeconomic headwinds like inflation, supply chain disruptions, and geopolitical tensions are broadly impacting the sector, leading to increased costs and potential delays in capital expenditures for healthcare providers. The significant restatement of RPO by Accuray highlights the complexities of revenue recognition under ASC 606 in an industry with long sales cycles and substantial capital equipment purchases, a challenge that other companies in the sector may also navigate.

Comparison to Industry Standards

• The significant reduction in Remaining Performance Obligations (RPO) from $866.0 million to $59.3 million due to an incorrect assessment of substantive termination penalties under ASC 606 is a substantial deviation from accurate financial reporting. This level of restatement for a key metric like RPO is highly unusual and suggests a fundamental flaw in the initial application of accounting standards, which would be considered a severe lapse compared to industry best practices for financial disclosure.
• The identification of material weaknesses in internal control over financial reporting (ICFR) and ineffective disclosure controls and procedures (DCP) as of September 30, 2025, indicates a failure to meet the robust internal control standards expected of publicly traded companies, especially those in the highly regulated medical device sector. Competitors like Varian Medical Systems (now Siemens Healthineers) and Elekta AB are expected to maintain stringent internal controls to ensure the reliability of their complex financial reporting.
• The increase in net loss to $(21,678) thousand for Q1 2026 from $(3,954) thousand in Q1 2025, coupled with a decrease in total net revenue from $101,545 thousand to $93,942 thousand, suggests a deteriorating financial performance. This trend contrasts with the general expectation for growth or stability in the oncology treatment market, where leading players often demonstrate more consistent revenue streams or clearer paths to profitability.
• The substantial increase in interest expense to $(8,052) thousand from $(2,955) thousand reflects a higher cost of debt, potentially indicating less favorable financing terms compared to larger, more financially stable industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings, claims, investigations, and inquiries arising in the ordinary course of its business.
• Management believes there are no probable and reasonably estimable material losses related to any current legal proceedings and claims as of September 30, 2025.
• Litigation is inherently unpredictable and subject to significant uncertainties, some of which are beyond the company's control.
• The company provides indemnities under software license agreements and standard indemnification agreements with landlords, but has not recorded any liability as no probable losses are identified.

Related Party Transactions

• The company has a joint venture (JV) with CNNC High Energy Equipment (Tianjin) Co., Ltd., a subsidiary of China Isotope & Radiation Corporation.
• Accounts receivable from the JV were $9,610 thousand as of September 30, 2025, and $28,452 thousand as of June 30, 2025.
• Other receivables from the JV were $359 thousand as of September 30, 2025, and $377 thousand as of June 30, 2025.
• Sales of products to the JV were $8,847 thousand during the three months ended September 30, 2025, compared to $28,644 thousand in the prior year period.
• Sales of services to the JV were $5,515 thousand during the three months ended September 30, 2025, compared to $4,058 thousand in the prior year period.
• Cost of revenue from sales to the JV was $9,545 thousand during the three months ended September 30, 2025, compared to $20,891 thousand in the prior year period.
• Charge backs to the JV related to research and development were $359 thousand during the three months ended September 30, 2025, compared to $355 thousand in the prior year period.
• Income from equity method investment (JV) was $439 thousand for the three months ended September 30, 2025, compared to a loss of $(72) thousand in the prior year period.
• The JV declared a $2.5 million dividend to the company in June 2025, which was paid in July 2025.
• The JV partner is a Chinese state-owned entity, which exposes the company to commercial, operational, and reputational risks due to potential politically motivated business decisions.
• CNNC, the JV partner's parent company, is on the U.S. Department of Defense's list of Chinese Military Companies, which may result in negative publicity and impact the JV.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity issuances and warrant exercises, and a likely decline in stock price due to the restatement, material weaknesses, and deteriorating financial performance.
• Employees are impacted by a 3% global workforce reduction as part of a cost savings initiative, potentially leading to increased workload for remaining staff and uncertainty.
• Customers may experience delays in product shipments and installations due to macroeconomic factors and supply chain issues, alongside reduced budgets for radiotherapy equipment.
• Suppliers, particularly single-source providers, are critical to the company's operations, and disruptions could lead to increased costs and inability to meet demand.
• Creditors are exposed to the company's substantial indebtedness, with assets pledged as collateral, making compliance with financial covenants crucial to avoid default.

Next Steps

• Remediate material weaknesses related to footnote disclosure review process and analysis of information for GAAP presentation.
• Continue to evaluate and modify the remediation plan as appropriate.
• Implement enhanced review controls specific to financial statement footnote disclosures, including additional reviewer involvement and targeted training.
• Implement enhanced controls to ensure all relevant information for complete and accurate presentation and disclosure, including initial assessment of new accounting pronouncements, is appropriately analyzed.
• The cost-saving initiative (workforce reduction) is expected to be substantially completed by the fourth quarter of fiscal year 2026.
• The company will adopt ASU 2023-09 (income tax disclosures) in its Annual Report on Form 10-K for fiscal 2026.
• The company plans to adopt ASU 2024-03 (expense disclosures) on July 1, 2027.
• The company will continue to monitor its recorded goodwill for indicators of impairment every fiscal quarter.
• The company is engaging in a significant organizational, strategic, and operational transformation.
• New CEO Stephen La Neve will lead the company's planning and execution of strategic, organizational, cultural, and operational initiatives.
• Steven F. Mayer will provide consulting services as Transformation Board Sponsor for one year.

Key Dates

Recommendation

The restatement of a key financial metric (RPO) by over 90%, coupled with the admission of material weaknesses in internal controls, signals severe deficiencies in financial reporting and corporate governance. The significant increase in net loss, decline in revenue, and rising interest expenses indicate deteriorating financial health. These issues, combined with ongoing macroeconomic headwinds, supply chain challenges, and the inherent risks of the medical device industry, present a highly unfavorable outlook for investors.

Keywords

Accuray, 10-Q/A, restatement, financial reporting, internal controls, material weakness, ASC 606, revenue recognition, remaining performance obligations, RPO, net loss, medical devices, radiation therapy, oncology, CyberKnife, TomoTherapy, SEC filing, corporate governance, financial performance, debt, capital raise, management changes